Drugs / AVX/COVID-12-HEXAPRO
AVX/COVID-12-HEXAPRO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04871737 | May 2021 → Aug 2022 | COVID-19 | Laboratorio Avi-Mex, S.A. de C.V. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-07-21 | CastleVax Inc. | Results Promising Results of Next-Generation Intranasal COVID-19 Booster Vaccine: Implications for Infection Prevention and Transmission castlevax.com ↗
Interim results show that intranasal delivery resulted in a robust S-specific, secretory IgA response in saliva relative to pre-booster levels, which is important for conferring mucosal immunity and has the potential to prevent infection and/or transmission of COVID-19. |
| 2023-05-04 | Laboratorio Avi-Mex, S.A. de C.V. | Results La etapa de desarrollo clínico del proyecto VACUNAL PATRIA® arroja datos favorables (AVX/COVID-12) com.mx ↗
La vacuna Patria® genera anticuerpos similares a una vacuna aprobada por la OMS de acuerdo con los datos disponibles de la Etapa Final de Desarrollo Clínico, como vacuna de refuerzo. |
| 2022-02-14 | Laboratorio Avi-Mex, S.A. de C.V. | Results Avimex® resultados preliminares de la FASE 1 clínica del proyecto VACUNAL PATRIA® com.mx ↗
Los resultados preliminares de la Fase Clínica I del proyecto vacunal Patria señalan que es un biológico seguro y con potencial de inmunogenicidad en seres humanos. |
| 2022-02-09 | CastleVax Inc. | Results Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route castlevax.com ↗
In the interim analysis reported here, the vaccine was found to be safe and the higher doses tested were found to be immunogenic |
| 2021-11-12 | Laboratorio Avi-Mex, S.A. de C.V. | Results Avimex® anuncia la publicación de datos Preclínicos en cerdos de la VACUNA PATRIA® (AVX/COVID-12) com.mx ↗
Las pruebas en cerdos de la vacuna mexicana Patria® mostraron que tanto la administración intranasal como intramuscular, así como una combinación de ambas, induce respuestas robustas de anticuerpos, incluyendo contra las variantes de interés. |
All press releases naming this drug 7 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVX/COVID-12-HEXAPRO | “Here we evaluated a vaccine candidate based on a live recombinant Newcastle disease virus (NDV) that expresses a stable version of the spike protein in infected cells as well...” PMID 37164959 ↗ May 2023 |
| Known as | NDV-HXP-S | “Here we evaluated a vaccine candidate based on a live recombinant Newcastle disease virus (NDV) that expresses a stable version of the spike protein in infected cells as well...” PMID 37164959 ↗ May 2023 |
| Known as | Patria | “Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results...” PMID 35169806 ↗ Feb 2022 |
| Modality | Vaccine | “a vaccine candidate based on a live recombinant Newcastle disease virus (NDV)” PMID 37164959 ↗ May 2023 |
| Route | Intranasal | “administered intranasally” PMID 37164959 ↗ May 2023 |